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euromodulation is a new promising treatment for headache disorders. It consists of peripheral nerve neurostimulation and central
neurostimulation.
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Neuromodulation (peripheral nerve neurostimulation [PNS] and central neurostimulation [CNS]) is a
new promising treatment for headache disorders. PNS includes occipital nerve stimulation (ONS),
vagal nerve stimulation (VNS), and stimulation that targets the supraorbital and sphenopalatine
ganglion (SPG) stimulation. CNS includes single pulse transcranial magnetic stimulation (sTMS).

Occipital nerve stimulation
Nociceptive inputs from dural and C-2 afferents converge in the brainstem trigeminal nucleus
caudalis (TNC). Second-order neurons in the spinal cord and the TNC are modulated by
descending projections from the periaqueductal gray (PAG); nucleus raphe magnus (NRM); and
the rostroventral medulla (RVM).1,2 ONS might exert its action by decreasing excitability of secondorder nociceptors in the TNC.3 ONS may restore balance within dysfunctional pain control centers.
ONS may be a symptomatic treatment and does not change disease outcome, since cranial
autonomic features persist in the absence of pain in some patients4 and painful attacks return if
stimulation is discontinued.5
There are three controlled trials of ONS in patients with chronic migraine (CM). Subjects in the Occipital
Nerve Stimulation for the Treatment of Chronic Migraine Headache (ONSTIM) study were randomized
to: adjustable stimulation (AS); sham stimulation (PS); or continued medical management (MM).6
Many outcomes showed numerical superiority (although not necessarily statistically significant
superiority) of AS over PS and over continued MM. Three-month responder rates were 39% for AS, 6%
for PS, and 0% for MM.
A second prospective, randomized, multicenter, double-blind, controlled study enrolled 125 subjects
with CM. They were implanted with a neurostimulation system (St Jude Medical Neuromodulation
Division, Plano, TX) and randomized to an active or control group for 12 weeks.7 Although there
was not a significant group difference in the number of patients with a 50% reduction on the
visual analog scale (primary endpoint), there was a significant difference at 30% (p<0.05), which is
considered clinically significant.
In a third prospective, double-blind, randomized, controlled, multicenter trial, 139 patients were
randomized to receive either active stimulation or PS.8 At 12 weeks ONS did not produce statistically
significant benefits in relation to PS on the primary endpoint.

Sphenopalatine ganglion stimulation
SPG contains parasympathetic efferents destined for meningeal blood vessels, the lacrimal gland,
and nasal mucosa. SPG stimulation may work by either interrupting SPG parasympathetic outflow or
modulating the sensory processing in TNC via slow neuromodulatory changes to the pain processing
structures of the brain stem.9 A US multicenter, randomized, sham-controlled study evaluating an
implanted SPG neurostimulator for the treatment of cluster headache is now underway.
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Supraorbital nerve stimulation

Central neurostimulation

The efficacy of a transcutaneous supraorbital stimulator (Cefaly, STX-Med.,
Herstal, Belgium) in migraine prevention was tested in a double-blinded,
randomized, sham-controlled trial.10 The 50% responder rate was significantly
greater (p<0.023) in the active group (38.1%) than in the sham group (12.1%).

sTMS is a safe, noninvasive method by which weak electrical currents
are induced in the brain by a rapidly changing magnetic field.15 When
sTMS is applied to the head, the magnetic field passes through the skull,
inducing mild electric currents in the brain that excite and depolarize
neurons in the brain. sTMS in animal models inhibits cortical spreading
depression and significantly decrease spontaneous neuronal firing of
third order thalamic neurons and C-fiber activity in response to dural
vessel stimulation.

Vagal nerve stimulation
VNS has been studied as a treatment for migraine and other primary
headache disorders. In three retrospective studies, at least 50% reported a
substantial (>50%) reduction in migraine frequency after at least 6 months
of stimulation.11,12 In an open-label, single-arm, multiple-attack study,
26 migraine patients were treated for 79 moderate or severe migraine
attacks (or treated after 20 minutes of mild pain) with two 90-second
doses at 15-minute intervals, delivered to the right cervical branch of the
vagus nerve.13 At 2 hours, headache response rate (pain mild or absent at
2 hours) was 46/79 (58%), and 22/79 patients (28%) were pain-free. At 2
hours, 76 of 79 (96%) were improved or had not worsened over baseline.
Treatment-related adverse effects were limited to transient muscle or local
tissue irritation and two reports of lightheadedness, most of which resolved
immediately after treatment and all within 2 hours of treatment.
VNS may suppress the development of central trigeminal sensitization.
Using a rat model of trigeminal allodynia, noninvasive VNS (nVNS)
suppressed the behavioral response and neurotransmitter changes
following the induction of trigeminal pain by infusing an inflammatory
cocktail onto the dura in awake rats three times per week for 4 weeks.14
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sTMS was tested in individuals with migraine based on the hypothesis
that a fluctuating magnetic field delivered by the device would, when
applied to the back of the head, induce electrical current and disrupt
cortical spreading depression. A randomized, double-blind, parallelgroup, multicenter, two-phase, sham-controlled study that enrolled 267
adults was conducted,16 in which all individuals had to meet International
Classification of Headache Disorders II criteria for migraine with aura,
with visual aura preceding at least 30% of migraines, followed by
moderate or severe headache in more than 90% of those attacks. Painfree response rates after two hours were significantly higher with sTMS
(32/82 [39%]) than with PS (18/82 [22%]), for a therapeutic gain of 17%
(95% confidence interval [CI] 3–31%; p=0.0179). Sustained pain-free
response rates significantly favored sTMS at 24 hours and 48 hours posttreatment. No device-related serious adverse events were recorded, and
incidence and severity of adverse events were similar between sTMS
and sham groups. q
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